MOBILion Systems, Inc. CEO Melissa Sherman Ph.D. highlighted a fundamental challenge: complexity in mass spectrometry.
Published
Signal category
Research & Knowledge
Quote
“Technology Networks recently asked leaders across the industry that question. The answers ranged from automation and AI to parallelization, sustainability, software, and accessibility.”
— MOBILion Systems, Inc. team
Company
MOBILion Systems, Inc.
The MOBILion team is focused on developing instruments that improve how we predict, diagnose and treat disease.
- Industry
- Biotechnology
- Location
- Chadds Ford, US
- Company size
- 42 employees
MOBILion’s technology makes it easy to separate, identify and analyze the most challenging molecules that other instruments fail to detect. Our higher resolution, faster analysis and simpler workflows reveal molecules that are most important in characterizing biologic therapeutics, discovering biomarkers, and improving the accuracy of diagnostic tests. We make today’s treatment’s safer and more effective, empower tomorrow’s disease prediction and diagnosis, and accelerate the development of new therapies.
Founded 2015